News for LUNG Stock

Pulmonx Reports Second Quarter 2025 Financial Results Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025 Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference Pulmonx Reports First Quarter 2025 Financial Results Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025 Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Pulmonx to Present at the Stifel 2024 Healthcare Conference Pulmonx Reports Third Quarter 2024 Financial Results Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024 Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024 Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference Pulmonx Reports Second Quarter 2024 Financial Results Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024 Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Pulmonx Reports First Quarter 2024 Financial Results Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024 Derrick Sung Joins Aerin Medical as Chief Financial Officer Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference Pulmonx to Participate at Upcoming Investor Conferences Pulmonx Reports Record Third Quarter 2023 Financial Results Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023 Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue Pulmonx to Participate at Upcoming Investor Conferences Pulmonx Reports Second Quarter 2023 Financial Results Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023 Pulmonx Reports First Quarter 2023 Financial Results Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023 Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results Pulmonx to Present at the Citi 2023 Healthcare Conference Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference Pulmonx to Participate at Upcoming Investor Conferences Pulmonx Reports Third Quarter 2022 Financial Results Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022 ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema Pulmonx to Present at Upcoming September Investor Conferences Pulmonx Reports Second Quarter 2022 Financial Results Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022 Pulmonx Reports First Quarter 2022 Financial Results Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022 Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference Pulmonx to Participate at Upcoming Investor Conferences Pulmonx Reports Third Quarter 2021 Financial Results Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021 Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment Pulmonx to Present at Upcoming September Investor Conferences Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment Pulmonx Reports Second Quarter 2021 Financial Results Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021 Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema Pulmonx Reports First Quarter 2021 Financial Results Pulmonx Corporation Expands Leadership Team Pulmonx to Present at BofA Securities 2021 Virtual Health Care Conference Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021 Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021 JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD Pulmonx Reports Third Quarter 2020 Financial Results Pulmonx to Present at Upcoming Investor Conferences Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD) Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020 Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering